valsartan has been researched along with Genetic Predisposition in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axelsson Raja, A; Bach, RG; Becker, JR; Benson, L; Bundgaard, H; Canter, C; Cirino, AL; Colan, SD; Day, SM; Ho, CY; Lakdawala, NK; Lever, HM; MacRae, CA; Margossian, R; McMurray, JJV; Mestroni, L; Murphy, AM; Orav, EJ; Owens, AT; Patel, AR; Pereira, AC; Rossano, JW; Russell, MW; Seidman, CE; Solomon, SD; Soslow, JH; Taylor, MRG; Thrush, P; Vissing, CR; Wheeler, MT; Wilmot, I; Zahka, K | 1 |
| Ahmed, A; Banach, M; Bielecka-Dabrowa, A; Misztal, M; Pietrucha, T; Rysz, J; Sakowicz, A; von Haehling, S | 1 |
| Peng, W; Qiao, H; Wang, L; Wang, Y; Wu, C; Xu, Z; Zhang, X | 1 |
| Wang, YP; Wang, YY; Xiao, ZX; Zhang, QY; Zhao, C | 1 |
| Barclay, BW; Navarrete, AE; Sahota, P; Webb, RL; Wosu, NJ | 1 |
2 trial(s) available for valsartan and Genetic Predisposition
| Article | Year |
|---|---|
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.
Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Child; Female; Genetic Predisposition to Disease; Humans; Hypertrophy, Left Ventricular; Male; Valsartan; Ventricular Remodeling | 2023 |
[The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Female; Genetic Predisposition to Disease; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Tetrazoles; Time Factors; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan | 2007 |
3 other study(ies) available for valsartan and Genetic Predisposition
| Article | Year |
|---|---|
Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Female; Genetic Markers; Genetic Predisposition to Disease; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Stroke Volume; Syndecan-4; Tetrazoles; Transforming Growth Factor beta1; Valsartan | 2016 |
The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.
Topics: Diabetic Nephropathies; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Protective Agents; Valsartan | 2016 |
Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cerebrovascular Disorders; Genetic Predisposition to Disease; Heart Rate; Hypertension; Infusion Pumps; Kidney; Myocardium; Proteinuria; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Sodium Chloride; Tetrazoles; Valine; Valsartan | 1998 |